We scan new podcasts and send you the top 5 insights daily.
Psychiatry drug development routinely suffers from an absence of functional pharmacodynamic biomarkers. Draig addressed this in Phase 1 by implementing magnetoencephalography (MEG) within single- and repeat-dose crossover trial designs. Measuring direct functional brain responses across dose levels within participants boosted assay sensitivity and generated objective pharmacodynamic evidence, which directly informed dose selection for subsequent Phase 2 trials.
The initial goal of precision psychiatry isn't complex machine learning or perfect biomarkers. It's about systematically collecting basic, meaningful data—like cognitive function—that we already know correlates with treatment outcomes. This simple act of consistent measurement provides a powerful foundation for better understanding patients.
Standard regulatory frameworks recognize fast antidepressant onset within seven days. However, Draig purposefully engineered DT101 with a pulsatile pharmacokinetic profile that allows transient AMPA receptor engagement. Inder Kaul notes this design mechanistically aligns with the synaptic plasticity biology demonstrated by esketamine and psychedelics, aiming to separate from placebo and drive robust, durable antidepressant efficacy as early as day four.
Rather than committing exclusively to monotherapy or adjunctive indications, Draig launched two concurrent Phase 2 studies. A global monotherapy study isolates DT101's dose response without confounding background therapies, confirming biological activity. Simultaneously, a US adjunctive study tests the asset on top of standard antidepressants, matching the commercial standard of care where patients failing frontline generic SSRIs or SNRIs require background combination regimens.
Instead of a traditional biomarker-first approach, Alto took a drug already approved in Europe (agomelatine) and used machine learning on patient EEG data to discover a novel biomarker that predicts who responds best. This "reverse-engineering" approach de-risks development by finding a precise population for a proven drug.
In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.
For CNS diseases, where animal models are notoriously unreliable predictors of efficacy, the most pragmatic R&D model is to quickly move promising new chemical entities into human trials. The focus shifts from extensive preclinical validation to early biological experimentation in humans for proof-of-concept.
The extensive translational and biomarker work published in Nature from a Phase 1 study of Casdatifan is a model for modern drug development. Understanding the drug's mechanism, pharmacodynamics, and response signatures from day one provides a 'backup plan' and helps avoid costly Phase 3 failures.
Serenatus Bio's Phase 1b study for its lead OCD drug incorporates 7-Tesla MRS imaging to directly measure the drug's effect on the brain's glutamate-GABA balance. This provides a clear "target engagement" signal, confirming the biological mechanism before a larger efficacy trial and significantly de-risking the program.
By continuously measuring a drug's effect on the body (pharmacodynamics), the wearable device provides a real-time view of a patient's phenotype. This granular data can revolutionize clinical trial design, safety monitoring, and drug dosing, moving beyond static genomic data to understand real-world drug response.
Unusually for a Phase 1 safety trial, Gain Therapeutics measured lipid levels in patients' cerebrospinal fluid. They observed a decrease in the target toxic lipids, providing strong, early biological evidence that the drug reaches the brain and works as intended. This de-risks future development by establishing a clear biomarker of effect.